Stock Track | Altimmune (ALT) Plummets 10.64% Despite Positive Phase 1b Data Showing Pemvidutide Reduces Inflammatory Lipids in MASH Patients

Stock Track11-16

Altimmune, Inc. (ALT) stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASH).

The data, presented at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases, showed that once-weekly subcutaneous doses of pemvidutide resulted in significant reductions in multiple classes of inflammatory lipids associated with increased cardiovascular disease risk and atherosclerosis progression.

Specifically, pemvidutide rapidly and markedly reduced levels of small atherogenic LDL particles compared to placebo in MASH patients with overweight or obesity. These findings suggest pemvidutide could potentially help address major comorbidities of MASH beyond just reducing liver fat, such as cardiovascular disease, atherosclerosis, and metabolic syndrome.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111457015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 00:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111457015","market":"us","top_or_hot":-1,"title":"Stock Track | Altimmune (ALT) Plummets 10.64% Despite Positive Phase 1b Data Showing Pemvidutide Reduces Inflammatory Lipids in MASH Patients","media":"Stock Track","content":"<p>Altimmune, Inc. (ALT) stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASH).</p>\n\n<p>The data, presented at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases, showed that once-weekly subcutaneous doses of pemvidutide resulted in significant reductions in multiple classes of inflammatory lipids associated with increased cardiovascular disease risk and atherosclerosis progression.</p>\n\n<p>Specifically, pemvidutide rapidly and markedly reduced levels of small atherogenic LDL particles compared to placebo in MASH patients with overweight or obesity. These findings suggest pemvidutide could potentially help address major comorbidities of MASH beyond just reducing liver fat, such as cardiovascular disease, atherosclerosis, and metabolic syndrome.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Altimmune (ALT) Plummets 10.64% Despite Positive Phase 1b Data Showing Pemvidutide Reduces Inflammatory Lipids in MASH Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Altimmune (ALT) Plummets 10.64% Despite Positive Phase 1b Data Showing Pemvidutide Reduces Inflammatory Lipids in MASH Patients\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-16 00:26 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Altimmune, Inc. (ALT) stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALT","symbol_name":"Altimmune, Inc.","start_time":0,"source_url":"","article_id":"1111457015","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111457015","pubTimestamp":1731687988,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Altimmune, Inc.  stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease .The data, presented at The Liver Meeting 2024 of the American Association for the Study of Liver Diseases, showed that once-weekly subcutaneous doses of pemvidutide resulted in significant reductions in multiple classes of inflammatory lipids associated with increase","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALT":"Altimmune, Inc."},"translate_title":"尽管积极的1b期数据显示Pemvidutide可减少MASH患者的炎症脂质，但Altimmune(ALT)仍暴跌10.64%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":1},"content_text":"Altimmune, Inc. (ALT) stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASH).\nThe data, presented at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases, showed that once-weekly subcutaneous doses of pemvidutide resulted in significant reductions in multiple classes of inflammatory lipids associated with increased cardiovascular disease risk and atherosclerosis progression.\nSpecifically, pemvidutide rapidly and markedly reduced levels of small atherogenic LDL particles compared to placebo in MASH patients with overweight or obesity. These findings suggest pemvidutide could potentially help address major comorbidities of MASH beyond just reducing liver fat, such as cardiovascular disease, atherosclerosis, and metabolic syndrome.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111457015"}